{
"id":"mk19_b_pm_t32",
"number":32,
"bookId":"pm",
"title":{
"__html":"Pharmacologic Therapy for Pulmonary Arterial Hypertension"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6ddd48",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 32. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t32"
}
]
},
"Pharmacologic Therapy for Pulmonary Arterial Hypertension"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3596ea",
"class":"cell txt l",
"children":[
"Calcium channel blockers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3e261",
"class":"cell txt l",
"children":[
"Only for patients with acute vasodilator response at catheterization; acute response does not ensure chronic response; adverse effects such as hypotension can occur."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34f8ed",
"class":"cell txt l",
"children":[
"Prostacyclin analogues (epoprostenol, treprostinil, iloprost)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9b221",
"class":"cell txt l",
"children":[
"Parenteral prostacyclin analogues such as epoprostenol, administered by a continuous central venous or subcutaneous infusion, are first-line therapy for severe disease and for those in whom disease progresses despite oral therapy; inhaled iloprost and treprostinil require frequent administration; oral treprostinil is most effective at higher doses (â‰¥9 mg/day); prostanoids supplement endogenous levels of prostacyclin (PGI",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"), a vasodilator with antismooth muscle proliferative properties."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a225e2",
"class":"cell txt l",
"children":[
"Prostacyclin receptor agonist (selexipag)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c1ef2",
"class":"cell txt l",
"children":[
"Works as an oral prostacyclin agonist. Current guidelines do not make recommendations for or against the use of selexipag for mild to moderate disease.",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b72fe1",
"class":"cell txt l",
"children":[
"Endothelin-1 receptor antagonists (bosentan, ambrisentan, macitentan)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d8a47",
"class":"cell txt l",
"children":[
"Reasonable initial oral therapies for mild to moderate disease.",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
" Blocks action of endogenous vasoconstrictor and smooth muscle mitogen endothelin; class-wide risk for liver injury and teratogenicity. Bosentan caries significant risk for liver injury and requires serial liver chemistry testing.",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
" Continuous pregnancy testing for reproductive-aged women is required."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01296f",
"class":"cell txt l",
"children":[
"Phosphodiesterase-5 inhibitors (sildenafil, tadalafil)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bbff9b",
"class":"cell txt l",
"children":[
"Reasonable initial oral therapies for mild to moderate disease.",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
" Prolongs effect of intrinsic vasodilator cyclic GMP by inhibiting hydrolysis by phosphodiesterase-5."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"402c7a",
"class":"cell txt l",
"children":[
"Soluble cyclic GMP stimulators (riociguat)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10e2ad",
"class":"cell txt l",
"children":[
"Reasonable initial oral therapy for mild to moderate disease. Works by directly stimulating guanylate cyclase receptor, independent of endogenous NO, to promote pulmonary artery vasodilation."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"GMP = guanosine monophosphate; NO = nitric oxide."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"The 2018 CHEST Guidelines for the treatment of pulmonary hypertension in adults made recommendations based largely on 6-minute walk test improvements in patients on various therapies. Selexipag improved other patient outcomes in a large, double-blind placebo controlled randomized clinical trial (GRIPHON). The guideline committee acknowledged that selexipag improved outcomes in other areas than the 6-minute walk test but did not recommend for or against its use given only modest improvement of 12 m in the treatment group compared with placebo."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Combination therapy with ambrisentan and tadalafil is the recommended first-line therapy in if the patient is willing and able to tolerate it."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Although not required for ambrisentan, some experts suggest that it is prudent to perform liver chemistry tests at the outset of treatment for pulmonary arterial hypertension and at periodic intervals thereafter at the discretion of the managing physician."
]
]
}